|
|
|
|
High Inoculum Pseudomonas aeruginosa Attenuates Colistin Bactericidal Activity Characterized by a New Mechanism-based Population Pharmacodynamic Model [Article]
High Inoculum Pseudomonas aeruginosa Attenuates Colistin Bactericidal Activity Characterized by a New Mechanism-based Population Pharmacodynamic Model Jrgen B.Bulitta*, Jenny C. Yang, Liliana Yohonn, Neang S. Ly, Silvia V. Brown, Rebecca E. D...
|
|
|
Discovery and Characterization of Inhibitors of Pseudomonas aeruginosa Type III Secretion [Article]
Discovery and Characterization of Inhibitors of Pseudomonas aeruginosa Type III Secretion Daniel Aiello, John D.Williams, Helena Majgier-Baranowska, Ishan Patel, Norton P. Peet, Jin Huang, Stephen Lory, Terry L. Bowlin, and Donald T. Moir*...
|
|
|
Azithromycin Alters Macrophage Phenotype and Pulmonary Compartmentalization during Pseudomonas Pneumonia [Article]
Azithromycin Alters Macrophage Phenotype and Pulmonary Compartmentalization during Pseudomonas Pneumonia David J.Feola*, Beth A. Garvy, Theodore J. Cory, Susan E. Birket, Heather Hoy, Don Hayes Jr., and Brian S. Murphy Departments of Pharmacy...
|
|
|
Efflux Pumps, OprD Porin, AmpC {beta}-Lactamase and Multiresistance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis [Article]
Expression of ampC, oprD , mexA , mexC , mexE , and mexX was studied in 25 Pseudomonas aeruginosa from cystic fibrosis patients, including 14 isolates of the Liverpool epidemic strain.Overexpressed mexA or ampC and reduced oprD were associated with ...
|
|
|
Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis - a pilot randomized controlled trial
Pseudomonas aeruginosa forms biofilms in the cystic fibrosis lung.Quorum sensing (QS) controls biofilm maturation, immune evasion, antibiotic tolerance and virulence factor production. Garlic shows QS inhibitory activity in vitro and in animal models...
|
|
|
FDA actions in brief, March 2010 (Iprivask, VPRIV, Mirapex ER, Cayston, Menveo, Lamictal XR, Rituxan, Oleptro,
Drugs and indications recently approved by the FDA Formulary Desirudin for injection (Iprivask, Canyon) was approved for the prevention of deep vein thrombosis.Velaglucerase alfa for injection (VPRIV, Shire) was approved for the long-term treatment of type 1...
|
|
|
Crystal Structure of the Narrow-Spectrum OXA-46 Class D {beta}-lactamase: Relationship between Active Site Lysine Carbamylation and Inhibition by Polycarboxylates [Article]
Crystal Structure of the Narrow-Spectrum OXA-46 Class D -lactamase: Relationship between Active Site Lysine Carbamylation and Inhibition by Polycarboxylates Jean-Denis Docquier, Manuela Benvenuti, Vito Calderone, Francesco Giuliani, Dimos Kapetis, Filomena De...
|
|
|
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese
_ Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese.
|
|
|
Potential of doripenem for the treatment of infections with multidrug-resistant Pseudomonas spp
_ Potential of doripenem for the treatment of infections with multidrug-resistant Pseudomonas spp.
|
|
|
Tat Pathway-Mediated Translocation of the Sec Pathway Substrate Protein MexA, an Inner Membrane Component of t
Pseudomonas aeruginosa is equipped with the Sec and Tat protein secretion systems, which translocate the xenobiotic transporter MexAB-OprM and the pathogenic factor phospholipase C (PlcH), respectively.When the signal sequence of MexA was replaced with...
|
|
|
Penicillin Sulfone Inhibitors of Class D -Lactamases
OXA -lactamases are largely responsible for -lactam resistance in Acinetobacter spp.and Pseudomonas aeruginosa, two of the most difficult-to-treat nosocomial pathogens. In general, the -lactamase inhibitors used in clinical practice (clavulanic acid,...
|
|
|
Activeion Cleaning Solutions announces new European subsidiary, Activeion GmbH
Activeion Cleaning Solutions LLC, Rogers, MN USA is proud to announce its new European subsidiary, Activeion (Europe) GmbH.Activeion (Europe) GmbH will distribute and market the ionator EXP throughout Europe, the Middle East and Africa. Activeion's ionator...
|
|
|
Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations
Fothergill JL et al.The results of this study are indicative that significant fluctuations occur within P. Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary...
|
|
|
The epidemiology of recurrent Gram-negative bacteremia in a tertiary-care hospital
were reviewed for microbial etiology and susceptibilities.Patient charts were reviewed to determine the source of infection and outcome. Results Forty-five nosocomial Gram-negative bacteremias occurred in 44 patients. Infection rates of 6.9/1000...
DiagnosticMicrobiology and Infectious Disease:
Mar 18 2010 7:26PM
Matching: pseudomonas
|
Find similar documents
|
|
|
|
In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections
Petersen PJ et al.Pseudomonas aeruginosa and several pathogens in the Proteeae group were generally less susceptible to tigecycline by comparison to other Gramnegative pathogens. In vitro activity of tigecycline against patient isolates collected...
|
|
|
Azithromycin Alters Macrophage Phenotype and Pulmonary Compartmentalization during Pseudomonas Pneumonia
David J.Feola*, Beth A. Garvy, Theodore J. Cory, Susan E. Birket, Heather Hoy, Don Hayes Jr., and Brian S. Murphy Departments of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky 40536; Departments of...
|
|
|
Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008
The study objective was to identify changes in cystic fibrosis (CF) sputum microbiology over 13 years.This study recruited a contemporary cohort of CF patients meeting similar eligibility criteria as the 520 subjects in the Phase 3 trials of inhaled tobramycin ...
|
|
|
Targeted antibiotics tackle bacterial resistance
Antibiotic resistance is increasing to such a level that there are fears that within 20 years antibiotics will cease to function, an eventuality that could take us back to the days before penicillin.Compounds that block the bacteria's pathogenicity instead...
|
|
|
Bayer obtains FDA orphan drug designation for cystic fibrosis drug
Bayer HealthCare Pharmaceuticals has reported that an orphan drug designation has been granted by the FDA for ciprofloxacin dry powder inhaler for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis, or CF, patients.
|
|
|
FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxaci
Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S.Food and Drug Administration (FDA) for ciprofloxacin dry powder inhaler (DPI) for management of pulmonary infection due to Pseudomonas...
|
|
|
FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis - Bayer Healthcare Pharmaceuticals
Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S.Food and Drug Administration for ciprofloxacin dry powder inhaler for management of pulmonary infection due to Pseudomonas aeruginosa in cystic...
|
|
|
Persistent Pseudomonas Aeruginosa Infections in CF Patients Have Molecular Basis
Small Colony Variants (SCVs) of P.aeruginosa to be a hallmark of chronic infection in cystic fibrosis (CF) patients, new research has revealed. Results, published March 12th in the open-access journal PLoS Pathogens, suggest that SCV-mediated persistence...
|
|
|
Molecular basis for Pseudomonas aeruginosa persistent infections in CF patients
New research reveals Small Colony Variants (SCVs) of P.aeruginosa to be a hallmark of chronic infection in cystic fibrosis (CF) patients. Results, published March 12th in the open-access journal PLoS Pathogens, suggest that SCV-mediated persistence might...
|
|
|
FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powd
WAYNE, N.J., March 11 (HSMN NewsFeed) -- Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S.Food and Drug Administration (FDA) for ciprofloxacin dry powder inhaler (DPI) for management of pulmonary...
|
|
|
TU Delft improves production of chemicals from wood waste
They discovered that the bacterium Cupriavidus basilensis breaks down harmful by-products which are produced when sugars are released from wood.They also managed to incorporate the degradation process in bacteria which are in common industrial use. This...
|
